strong execut control growth lever
updat model estim
clear final hurdl file ak program san antonio offer
 first look slight ep weak revenue
manag issu attract ep
analyst certif import disclosur see
sustain growth resourc optim
strong execut control growth lever
re-affirmed adj guidanc post adj ebitda/ep consensu in-lin revenu note
potenti weaker commod environ push time-frame achiev manag target
updat estim reflect current commod soft howev commod pictur remain fluid
view execut continu strong pull intern lever organ ebitda growth ex-commod
look catalyst late includ financi close proto newhurst commiss tap
support organ growth trajectori maintain rate
updat model estim
adjust estim line current guidanc retain estim adjust
estim line compani guidanc prior estim
retain estim believ upsid estim base revenu
coven state recent debt file debt commit believ overhang potenti equiti dilut
clear final hurdl file ak program san antonio offer near-term breast cancer catalyst
report one-year follow data actin keratosi ak recurr phase studi patient treat
tirbanibulin ointment also known import metric clinic
adoptionfocu day respons raterecurr data final compon clinic section emea fda
file view mileston materi de-risk event support potenti commerci launch
separ would look accumul share prior present matur surviv data phase oraxol
metastat breast cancer studi san antonio breast cancer meet begin decemb also see opportun
near-term asia partner oraxol
cloud
 first look slight ep weak revenue manag issu attract ep
 report normal revenu growth slightli estim oper ep came better
expect vs estimate postpaid phone net add prepaid net add saw vs
estim neg video subscrib metric acceler premium tv saw net loss compani
focus profit end promot host investor day tomorrow focus compani new
hbo max ott video offer attend manag issu three-year plan focus mani topic
relat elliot manag letter target ep debt-to-ebitda revenue growth per year
